- Home
- BEAT vs ATOS Comparison
BEAT vs ATOS Comparison
Compare BEAT & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | ATOS |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 24.1M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BEAT | ATOS |
|---|---|---|
| Price | $0.42 | $2.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.63 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 299.1K | 51.1K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $315.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.53 |
| 52 Week High | $4.00 | $7.56 |
Technical Indicators
Market Signals| Indicator | BEAT | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 47.80 |
| Support Level | N/A | $2.32 |
| Resistance Level | $0.52 | $2.60 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.18 | 37.34 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.